LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non–small-cell Lung Cancer

LACE-Bio Steering Committee

doi:10.1016/j.cllc.2018.10.001

LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non–small-cell Lung Cancer

LACE-Bio Steering Committee

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

There are no validated molecular tools to allow patient selection for adjuvant chemotherapy after complete resection of non–small-cell lung cancer. Immunohistochemistry biomarkers shown in one trial to have a prognostic/predictive effect on overall survival were tested. The majority of the promising biomarkers could not be validated, and none were predictive of benefit. Immunohistochemistry assays from single trials may be misleading. Background: Complete resection of non–small-cell lung cancer (NSCLC) offers the potential for cure after surgery and adjuvant chemotherapy. Patients may not benefit and may experience severe toxicity. There are no validated molecular tools to allow better patient selection. Materials and Methods: The LACE-Bio (LACE [Lung Adjuvant Cisplatin Evaluation]) project includes 4 trials (International Adjuvant Lung Cancer Trial [IALT], Adjuvant Navelbine International Trialist Association [ANITA], JBR10, and Cancer and Leukemia Group B (CALGB)-9633). Immunohistochemistry biomarkers shown in one trial to have a prognostic/predictive effect on overall survival were tested. Results: The majority of the promising biomarkers could not be validated; the prognostic effect of tumor infiltrating lymphocytes and β-tubulin was confirmed. Potential causes include tissue fixation, storage, the use of tissue microarrays, and varying reagent/antibody batches. Conclusions: Immunohistochemistry assays from single trials may be misleading and require validation before being used for patient selection. LACE-Bio-2 is evaluating potential genomic biomarkers that may allow more precise selection of patients with NSCLC for adjuvant chemotherapy in NSCLC.

Original language	English (US)
Pages (from-to)	66-73.e6
Journal	Clinical Lung Cancer
Volume	20
Issue number	2
DOIs	https://doi.org/10.1016/j.cllc.2018.10.001
State	Published - Mar 2019

Bibliographical note

Funding Information:
We have now implemented LACE-Bio2, investigating the utility of genomic-based biomarkers, funded in part by a National Institutes of Health RO-1 grant ( http://grantome.com/grant/NIH/R01-CA165958-02 ). Initial results suggest chromosomal instability and high nonsynonymous TMB (> 8 mutations/Mb) may have a prognostic effect, and we have identified new candidate prognostic markers. 38,39

Funding Information:
This work was supported by the Canadian Cancer Society Research Institute [grant #015469 and #021039], Institut National du Cancer (INCA) funding to J.-C. Soria, E. Brambilla (PNES and PHRC, Direction de la Recherche Clinique du CHUGA Grenoble), Ligue Nationale Contre le Cancer funding to the Meta-analysis Unit, and an unrestricted educational grant from Sanofi (France). The authors acknowledge Nicolas Lemaire for immunohistochemical technique.

Funding Information:
This work was supported by the Canadian Cancer Society Research Institute [grant # 015469 and # 021039 ], Institut National du Cancer (INCA) funding to J.-C. Soria, E. Brambilla (PNES and PHRC, Direction de la Recherche Clinique du CHUGA Grenoble), Ligue Nationale Contre le Cancer funding to the Meta-analysis Unit, and an unrestricted educational grant from Sanofi (France). The authors acknowledge Nicolas Lemaire for immunohistochemical technique.

Publisher Copyright:
© 2018 Elsevier Inc.

Keywords

Adjuvant chemotherapy
Biomarkers
NSCLC
Predicative
Prognostic

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.cllc.2018.10.001

OpenUrl availability

Full text

Cite this

@article{b7b3774187184f82b76e06d4152e7bac,

title = "LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non–small-cell Lung Cancer",

abstract = "There are no validated molecular tools to allow patient selection for adjuvant chemotherapy after complete resection of non–small-cell lung cancer. Immunohistochemistry biomarkers shown in one trial to have a prognostic/predictive effect on overall survival were tested. The majority of the promising biomarkers could not be validated, and none were predictive of benefit. Immunohistochemistry assays from single trials may be misleading. Background: Complete resection of non–small-cell lung cancer (NSCLC) offers the potential for cure after surgery and adjuvant chemotherapy. Patients may not benefit and may experience severe toxicity. There are no validated molecular tools to allow better patient selection. Materials and Methods: The LACE-Bio (LACE [Lung Adjuvant Cisplatin Evaluation]) project includes 4 trials (International Adjuvant Lung Cancer Trial [IALT], Adjuvant Navelbine International Trialist Association [ANITA], JBR10, and Cancer and Leukemia Group B (CALGB)-9633). Immunohistochemistry biomarkers shown in one trial to have a prognostic/predictive effect on overall survival were tested. Results: The majority of the promising biomarkers could not be validated; the prognostic effect of tumor infiltrating lymphocytes and β-tubulin was confirmed. Potential causes include tissue fixation, storage, the use of tissue microarrays, and varying reagent/antibody batches. Conclusions: Immunohistochemistry assays from single trials may be misleading and require validation before being used for patient selection. LACE-Bio-2 is evaluating potential genomic biomarkers that may allow more precise selection of patients with NSCLC for adjuvant chemotherapy in NSCLC.",

keywords = "Adjuvant chemotherapy, Biomarkers, NSCLC, Predicative, Prognostic",

author = "{LACE-Bio Steering Committee} and Lesley Seymour and {Le Teuff}, Gw{\'e}na{\"e}l and Elisabeth Brambilla and Shepherd, {Frances A.} and Soria, {Jean Charles} and Robert Kratzke and Stephen Graziano and Douillard, {Jean Yves} and Rafael Rosell and Anthony Reiman and Benjamin Lacas and Beranger Lueza and Sarit Aviel-Ronen and Anne McLeer and {Le Chevalier}, Thierry and Robert Pirker and Martin Filipits and Ariane Dunant and Pignon, {Jean Pierre} and Tsao, {Ming Sound}",

note = "Funding Information: We have now implemented LACE-Bio2, investigating the utility of genomic-based biomarkers, funded in part by a National Institutes of Health RO-1 grant ( http://grantome.com/grant/NIH/R01-CA165958-02 ). Initial results suggest chromosomal instability and high nonsynonymous TMB (> 8 mutations/Mb) may have a prognostic effect, and we have identified new candidate prognostic markers. 38,39 Funding Information: This work was supported by the Canadian Cancer Society Research Institute [grant #015469 and #021039], Institut National du Cancer (INCA) funding to J.-C. Soria, E. Brambilla (PNES and PHRC, Direction de la Recherche Clinique du CHUGA Grenoble), Ligue Nationale Contre le Cancer funding to the Meta-analysis Unit, and an unrestricted educational grant from Sanofi (France). The authors acknowledge Nicolas Lemaire for immunohistochemical technique. Funding Information: This work was supported by the Canadian Cancer Society Research Institute [grant # 015469 and # 021039 ], Institut National du Cancer (INCA) funding to J.-C. Soria, E. Brambilla (PNES and PHRC, Direction de la Recherche Clinique du CHUGA Grenoble), Ligue Nationale Contre le Cancer funding to the Meta-analysis Unit, and an unrestricted educational grant from Sanofi (France). The authors acknowledge Nicolas Lemaire for immunohistochemical technique. Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2019",

month = mar,

doi = "10.1016/j.cllc.2018.10.001",

language = "English (US)",

volume = "20",

pages = "66--73.e6",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - LACE-Bio

T2 - Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non–small-cell Lung Cancer

AU - LACE-Bio Steering Committee

AU - Seymour, Lesley

AU - Le Teuff, Gwénaël

AU - Brambilla, Elisabeth

AU - Shepherd, Frances A.

AU - Soria, Jean Charles

AU - Kratzke, Robert

AU - Graziano, Stephen

AU - Douillard, Jean Yves

AU - Rosell, Rafael

AU - Reiman, Anthony

AU - Lacas, Benjamin

AU - Lueza, Beranger

AU - Aviel-Ronen, Sarit

AU - McLeer, Anne

AU - Le Chevalier, Thierry

AU - Pirker, Robert

AU - Filipits, Martin

AU - Dunant, Ariane

AU - Pignon, Jean Pierre

AU - Tsao, Ming Sound

N1 - Funding Information: We have now implemented LACE-Bio2, investigating the utility of genomic-based biomarkers, funded in part by a National Institutes of Health RO-1 grant ( http://grantome.com/grant/NIH/R01-CA165958-02 ). Initial results suggest chromosomal instability and high nonsynonymous TMB (> 8 mutations/Mb) may have a prognostic effect, and we have identified new candidate prognostic markers. 38,39 Funding Information: This work was supported by the Canadian Cancer Society Research Institute [grant #015469 and #021039], Institut National du Cancer (INCA) funding to J.-C. Soria, E. Brambilla (PNES and PHRC, Direction de la Recherche Clinique du CHUGA Grenoble), Ligue Nationale Contre le Cancer funding to the Meta-analysis Unit, and an unrestricted educational grant from Sanofi (France). The authors acknowledge Nicolas Lemaire for immunohistochemical technique. Funding Information: This work was supported by the Canadian Cancer Society Research Institute [grant # 015469 and # 021039 ], Institut National du Cancer (INCA) funding to J.-C. Soria, E. Brambilla (PNES and PHRC, Direction de la Recherche Clinique du CHUGA Grenoble), Ligue Nationale Contre le Cancer funding to the Meta-analysis Unit, and an unrestricted educational grant from Sanofi (France). The authors acknowledge Nicolas Lemaire for immunohistochemical technique. Publisher Copyright: © 2018 Elsevier Inc.

PY - 2019/3

Y1 - 2019/3

N2 - There are no validated molecular tools to allow patient selection for adjuvant chemotherapy after complete resection of non–small-cell lung cancer. Immunohistochemistry biomarkers shown in one trial to have a prognostic/predictive effect on overall survival were tested. The majority of the promising biomarkers could not be validated, and none were predictive of benefit. Immunohistochemistry assays from single trials may be misleading. Background: Complete resection of non–small-cell lung cancer (NSCLC) offers the potential for cure after surgery and adjuvant chemotherapy. Patients may not benefit and may experience severe toxicity. There are no validated molecular tools to allow better patient selection. Materials and Methods: The LACE-Bio (LACE [Lung Adjuvant Cisplatin Evaluation]) project includes 4 trials (International Adjuvant Lung Cancer Trial [IALT], Adjuvant Navelbine International Trialist Association [ANITA], JBR10, and Cancer and Leukemia Group B (CALGB)-9633). Immunohistochemistry biomarkers shown in one trial to have a prognostic/predictive effect on overall survival were tested. Results: The majority of the promising biomarkers could not be validated; the prognostic effect of tumor infiltrating lymphocytes and β-tubulin was confirmed. Potential causes include tissue fixation, storage, the use of tissue microarrays, and varying reagent/antibody batches. Conclusions: Immunohistochemistry assays from single trials may be misleading and require validation before being used for patient selection. LACE-Bio-2 is evaluating potential genomic biomarkers that may allow more precise selection of patients with NSCLC for adjuvant chemotherapy in NSCLC.

AB - There are no validated molecular tools to allow patient selection for adjuvant chemotherapy after complete resection of non–small-cell lung cancer. Immunohistochemistry biomarkers shown in one trial to have a prognostic/predictive effect on overall survival were tested. The majority of the promising biomarkers could not be validated, and none were predictive of benefit. Immunohistochemistry assays from single trials may be misleading. Background: Complete resection of non–small-cell lung cancer (NSCLC) offers the potential for cure after surgery and adjuvant chemotherapy. Patients may not benefit and may experience severe toxicity. There are no validated molecular tools to allow better patient selection. Materials and Methods: The LACE-Bio (LACE [Lung Adjuvant Cisplatin Evaluation]) project includes 4 trials (International Adjuvant Lung Cancer Trial [IALT], Adjuvant Navelbine International Trialist Association [ANITA], JBR10, and Cancer and Leukemia Group B (CALGB)-9633). Immunohistochemistry biomarkers shown in one trial to have a prognostic/predictive effect on overall survival were tested. Results: The majority of the promising biomarkers could not be validated; the prognostic effect of tumor infiltrating lymphocytes and β-tubulin was confirmed. Potential causes include tissue fixation, storage, the use of tissue microarrays, and varying reagent/antibody batches. Conclusions: Immunohistochemistry assays from single trials may be misleading and require validation before being used for patient selection. LACE-Bio-2 is evaluating potential genomic biomarkers that may allow more precise selection of patients with NSCLC for adjuvant chemotherapy in NSCLC.

KW - Adjuvant chemotherapy

KW - Biomarkers

KW - NSCLC

KW - Predicative

KW - Prognostic

UR - http://www.scopus.com/inward/record.url?scp=85055967423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055967423&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2018.10.001

DO - 10.1016/j.cllc.2018.10.001

M3 - Article

C2 - 30414783

AN - SCOPUS:85055967423

SN - 1525-7304

VL - 20

SP - 66-73.e6

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 2

ER -

LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non–small-cell Lung Cancer

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this